Navigation Links
Idenix Announces Data Presentations at the 2007 Digestive Disease,Week Meeting

CAMBRIDGE, Mass., April 18, 2007 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases, announced today that 11 abstracts have been accepted for presentation at the 2007 Digestive Disease Week (DDW) meeting, to be held in Washington D.C. from May 19 to 24. The abstract contents are available on the DDW web site at .

Hepatitis C Abstracts:

Dr. Norman Gitlin, Professor of Medicine, Atlanta Gastroenterology Associations and Emory University, Atlanta, GA, will present "Valopicitabine (NM283) Plus Peg-Interferon Alfa-2a (peg-IFN) in Treatment-Naive Patients With HCV-1 Infection: Preliminary Results At Weeks 24 and 48" in a poster session beginning on Monday, May 21, 2007 at 8:00 a.m. Eastern Daylight Time (EDT).

Dr. Maribel Rodriguez-Torres, President, Fundacion de Investigacion de Diego, Santurce, Puerto Rico, will present "Final Results from a Phase IIA Pharmacokinetic Study of Valopicitabine (NM283) and Peg-IFNa-2b in Patients with Genotype 1 Chronic Hepatitis C" in a poster session beginning on Monday, May 21, 2007 at 8:00 a.m. EDT.

About Valopicitabine (NM283)

Valopicitabine is an investigational HCV RNA polymerase inhibitor being evaluated in ongoing clinical trials for the treatment of hepatitis C.

Hepatitis B Abstracts

Dr. Maria Seifer, Director, Biology at Idenix Pharmaceuticals, will present "Genotypic Analysis of Patients with Evaluable HBV DNA After 1 Year of Telbivudine Therapy in the GLOBE Registration Trial" in a meeting session on Sunday, May 20, 2007 at 11:15 a.m. EDT.

Dr. Steven Han, Associate Clinical Professor in the Division of Digestive Diseases and the Division of Liver and Pancreas Transplantation and Directo r of the UCLA Hepatology Clinical Research Center, will present "Telbivudine Globe Trial at Year Two: Efficacy, Safety, and Predictors of Outcome in Patients with Chronic Hepatitis B" in a poster session beginning on Sunday, May 20, 2007 at 8:00 a.m. EDT.

Dr. Steven Han will also present "Hepatitis B Patient Survey: Disease Understanding and Compliance in the United States" in a poster session beginning on Sunday, May 20, 2007 at 8:00 a.m. EDT.

Dr. Natalie Bzowej, Director of Clinical Hepatology Research at California Pacific Medical Center, will present "A Randomized Trial of Telbivudine vs. Adefovir for HBeAg-Positive Chronic Hepatitis B: Efficacy Through Week 76, Predictors of Response and Effects of Switching to Telbivudine" in a poster session beginning on Sunday, May 20, 2007 at 8:00 a.m. EDT.

Dr. Elizabeth J. Heathcote, Professor of Medicine at the University of Toronto Western Hospital, will present "Salvage Therapy with Adefovir for Virologic Breakthrough in Telbivudine-Treated Patients from the GLOBE Study" in a poster session beginning on Sunday, May 20, 2007 at 8:00 a.m. EDT.

Dr. Yuming Wang, Professor of Infectious Disease, Southwest Hospital, Chongqing, China, will present "A Phase III Comparative Trial of Telbivudine vs Lamivudine in Chinese Patients with Chronic Hepatitis B: Two- Year Results" in a poster session beginning on Sunday, May 20, 2007 at 8:00 a.m. EDT.

Dr. Vinod Rustgi, Co-Director of the Transplant Institute at Georgetown University School of Medicine and Clinical Professor of Medicine at the Medical College of Virginia, will present "A Survey of Hepatitis B Patient Demographics, Disease Characteristics and Management Practice in the United States" in a poster session beginning on Sunday, May 20, 2007 at 8:00 a.m. EDT.

Dr. Xiao-Jian Zhou, Director, Clinical Pharmacology at Idenix Pharmaceuticals, will present "Absence of Pharmacokinetic Drug-Drug Interaction Between Telbivudine and Tenofovir" in a poster session beginning on Sunday, May 20, 2007 at 8:00 a.m. EDT.

Dr. David Standring, Senior Vice President, Biology at Idenix Pharmaceuticals, will present "Resistance Determination in Patients Experiencing Virologic Breakthrough Following Telbivudine or Lamivudine Therapy in the International GLOBE Trial" in a poster session beginning on Sunday, May 20, 2007 at 8:00 a.m. EDT.

Important Information About TYZEKA(R) (telbivudine)

TYZEKA is indicated for the treatment of chronic hepatitis B in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. This indication is based on virologic, serologic, biochemical and histologic responses after one year of treatment in nucleoside-treatment-naive adult patients with HBeAg-positive and HbeAg-negative chronic hepatitis B with compensated liver disease. For full prescribing information please visit .

    Important Safety Information about TYZEKA (telbivudine)

    -- Lactic acidosis and severe hepatomegaly with steatosis, including fatal

       cases, have been reported with the use of nucleoside analogues alone or

       in combination with antiretrovirals. Severe acute exacerbations of

       hepatitis B have been reported in patients who have discontinued anti-

       hepatitis B therapy, including TYZEKA. Hepatic function should be

       monitored closely with both clinical and laboratory follow-up for at

       least several months in patients who discontinue anti-hepatitis B

       therapy. If appropriate, resumption of antihepatitis B therapy may be


    -- Cases of myopathy have been reported with TYZEKA use several weeks to

       months after starting therapy. Myopathy has also been reported with

       some other drugs in this class. Physicians considering concomitan

       treatment with these or other agents associated with myopathy should

       weigh carefully the potential benefits and risks and should monitor and

       advise patients to report any signs or symptoms of unexplained muscle

       pain, tenderness or weakness, particularly during periods of upward

       dosage titration. TYZEKA therapy should be interrupted if myopathy is

       suspected, and discontinued if myopathy is diagnosed.

    -- Because TYZEKA is eliminated primarily by renal excretion, co-

       administration of TYZEKA with drugs that affect renal function may

       alter plasma concentrations of TYZEKA and/or the coadministered drug.

       Dose interval adjustment is required in patients with creatinine

       clearance <50mL/min including those with end stage renal disease on

       hemodialysis. For patients on hemodialysis, telbivudine should be

       administered after hemodialysis.

    -- The safety and efficacy of TYZEKA in liver transplant recipients are

       unknown. If TYZEKA treatment is determined to be necessary for a liver

       transplant recipient who has received or is receiving an

       immunosuppressant that may affect renal function, such as cyclosporine

       or tacrolimus, renal function should be monitored both before and

       during treatment with TYZEKA.

    -- Patients should be advised that treatment with TYZEKA has not been

       shown to reduce the risk of transmission of HBV to others through

       sexual contact or blood contamination.

    -- Safety and effectiveness of TYZEKA in pediatric patients under the age

       of 16 years have not been established.

    -- Most common adverse events (>5%) in clinical studies, regardless of

       attributability to telbivudine, were upper respiratory tract infection

       (14%), fatigue and malaise (12%), abdominal pain (12%),

       nasopharyngitis (11%), headache (11%), blood CPK increased (9%), cough

       (7%), nausea and vo
miting (7%), influenza and influenza-like symptoms

       (7%), post-procedural pain (7%), diarrhea and loose stools (7%), and

       pharyngolaryngeal pain (5%).

    -- Grade 3-4 creatine kinase (CK) elevations occurred in 9% of TYZEKA-

       treated patients.

    -- The optimal duration of treatment with TYZEKA has not been established.

       The relationship of initial treatment response to outcomes such as

       hepatocellular carcinoma and decompensated cirrhosis are unknown.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, MA, is a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis B virus, hepatitis C virus and human immunodeficiency virus (HIV). For further information about Idenix, please refer to .

Forward-looking Statement

This press release may contain "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward- looking statements can be identified by the use of forward-looking terminology such as "will," or similar expressions, or by express or implied statements with respect to clinical trial development of telbivudine and valopicitabine. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantees that Idenix will successfully commercialize telbivudine, that TYZEKA(R) will ultimately be approved for sale by the European Commission, or in any additional markets, or that revenues from TYZEKA or any potential product will reach any particular level or that Idenix will advance any other clinic product candidate or other component of our potential pipeline in the clinic or in the regulatory process. In particular, management's expectations could be affected by unsuccessful efforts to commercialize TYZEKA or any other product candidate; unexpected regulatory actions or delays; uncertainties relating to results of clinical trials, including additional data relating to the ongoing clinical trials evaluating its product candidates; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; the company's dependence on its collaboration with Novartis Pharma AG; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain and enforce patent and other intellectual property protection for its other product candidates and its discoveries. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" in the company's annual report on Form 10-K for the year ended December 31, 2006 and filed with the Securities and Exchange Commission and other filings that the company makes with the Securities and Exchange Commission.

All forward-looking statements reflect the company's expectations only as of the date of this release and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. Idenix anticipates that subsequent events and developments may cause these views, expectations and beliefs to change. However, while Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Idenix Pharmaceuticals' Contact:

Investors: Amy Sullivan (617-995-9838)

Media: Teri Dahlman (617-995-9905)

CONTACT: Investors, Amy Sullivan, +1-617-995-9838, or Media, Teri Dahlman,+1-617-995-9905, both of Idenix Pharmaceuticals, Inc.

Web site:

Ticker Symbol: (NASDAQ-NMS:IDIX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Idenix Reports Results from Two Phase IIb Studies of the Combination of Valopicitabine and Pegylated Interferon in Hepatitis C Genotype-1 Patients at the 42nd Annual Meeting of the European Association for the Study of the Liver
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
(Date:9/18/2017)... R.I. , Sept. 18, 2017 /PRNewswire/ ... the fields of bioinformatics and immune engineering, ... a protective avian influenza A (H7N9) vaccine. ... distantly related to seasonal influenza and presents ... rely on prior exposure to be effective. ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 ... performance ratings for global supply chains, has published the first annual edition ... CSR performance of more than 20,400 companies evaluated by EcoVadis, based on ... 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... The International Association of Eating Disorders Professionals ... the field of eating disorders, announces the opening of early registration for the ... at the Omni Resort at ChampionsGate. , The annual iaedp™ Symposium ...
(Date:10/13/2017)... ... 2017 , ... Many families have long-term insurance that covers care for a ... waiver for care if the client has a cognitive impairment diagnosis. , “What ... is often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
Breaking Medicine News(10 mins):